• Economy
  • Investing
Long Distance Investing
  • Stock
  • Editor’s Pick
Investing

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Plans Preclinical Studies for Treatment of Monkey Pox

by September 9, 2024
written by September 9, 2024

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, is focused on beginning Proof of Concept preclinical studies to evaluate its lead therapeutic TCB 008 for treatment in monkey pox. According to the announcement, TCBP will partner with a leading infectious disease center or university associated with a similar organization to advance the studies as quickly as possible.

“There are a number of academic papers highlighting a successful immune response to viral infection being heavily reliant on the presence of gamma delta t-cells,” said TC BioPharm CEO Bryan Kobel in the press release. “We continue to look at avenues to expand the therapeutic applications for TCB008, and moving into rapid response for aggressive viral infections is an arena we believe our therapeutic can be immediately impactful. The ability to deliver a frozen/thawed product to these patients to prevent not just the death or extended viral infection in these patients, but also potentially slow the spread of the infectious disease and contain the issue from becoming a global pandemic, would represent a massive global opportunity and market size. We look forward to updating investors as we further this program.”

To view the full press release, visit https://ibn.fm/judx7

About TC Biopharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies and is the first company to conduct phase 2/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the company’s proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. For more information, please visit www.TCBioPharm.com.

NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://ibn.fm/TCBP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

The post BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Plans Preclinical Studies for Treatment of Monkey Pox appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
HII Delivers Advanced REMUS 620 UUVs to NOAA Less than 24 Months after Unveiling
next post
Chase Bank is referring check fraud ‘glitch’ incidents to authorities

You may also like

MEXC strengthens reserve backing with $390M asset increase

April 23, 2025

Oil prices rebound: what’s driving the rally and...

April 23, 2025

Silver rises with gold, but industrial demand outlook...

April 23, 2025

Lead Edge Capital founder Mitchell Green says recession...

April 23, 2025

Why is Toncoin price rising today?

April 23, 2025

BC.GAME to host ‘Untamed Arena’ during TOKEN2049 Dubai,...

April 23, 2025

Keycard launches pre-sale for Shell: the most open,...

April 23, 2025

BA stock rises as Boeing reports smaller Q1...

April 23, 2025

US stocks surge at open: Dow climbs 2.4%,...

April 23, 2025

iExec launches 1M $RLC fund to support AI...

April 23, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • White House accuses Powell of mismanaging Federal Reserve, citing headquarters renovation

      July 10, 2025
    • Italian chocolate giant Ferrero to buy Kellogg’s Froot Loops maker

      July 10, 2025
    • OpenAI to release web browser in challenge to Google Chrome

      July 10, 2025
    • Sports executive charged with bid-rigging in Texas arena project

      July 10, 2025

    Categories

    • Economy (785)
    • Editor's Pick (422)
    • Investing (4,555)
    • Stock (820)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: Longdistanceinvestings.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 Longdistanceinvestings.com

    Long Distance Investing
    • Economy
    • Investing
    Long Distance Investing
    • Stock
    • Editor’s Pick